Rokae (Shandong) Robotics Group began trading on the Main Board of the Hong Kong Stock Exchange under stock code 3752 on 9 July 2026, raising HK$875.2 million (about US$111.7 million) in a heavily oversubscribed global offering that valued the Chinese robotics maker at roughly HK$9.5 billion.
An Elevenfold-Oversubscribed Offering
The Beijing-headquartered company priced its offering at HK$38.00 per H share for 23,031,900 shares. The Hong Kong public offering was oversubscribed 156.58 times, according to Baker McKenzie, which acted as Rokae's Hong Kong and U.S. legal adviser alongside FenXun. Cornerstone investors including GF Management, Huatai Capital, Beijing Financial Street Capital, Yishao Capital and All View Focus Fund LPF took 31.4% of the deal.
A Rare Chinese Cobot Maker At Scale
Rokae is one of the first Chinese robotics companies to reach large-scale production of both industrial and collaborative robots, with annual output above 1,000 units and top-six rankings by revenue in China's industrial and cobot markets in 2025. It is also the only top-six Chinese cobot vendor with large-scale flexible collaborative-robot production capability and a top-five position in embodied intelligent robotic arms.
Adds To A China Robotics Listing Wave
Rokae joins a busy Chinese robotics listing pipeline: Unitree Robotics secured China Securities Regulatory Commission approval in early July for a Shanghai STAR Market IPO expected to raise about US$618 million, while humanoid peers UBTech and X-Variable Robotics push valuations past US$3 billion. Analysts see Rokae's book-build result as a fresh signal that Hong Kong is again a viable venue for advanced-manufacturing tech listings after several stalled deals, adding to a strong stretch for Chinese industrial robotics and China AI capital markets.
What The Money Funds
Rokae plans to use the proceeds to expand production of its xMate cobots, NB-series industrial arms and Human.X humanoid platform, and to deepen R&D on force-controlled joints and embodied AI. The company operates R&D centers in Beijing, Tokyo, Wuhan and Shandong and sells into more than 20 countries across auto parts, electronics, metal fabrication, healthcare and commercial services.
Reporting based on coverage from Baker McKenzie, Dealroom, Deloitte China, Minichart and South China Morning Post.